Formulation Considerations for Physical Stability of High Concentration Biologics
Posted on June 14, 2016
By: Ajit S. Narang, Principal Scientist
Mary E. Krause, Research Investigator
Aastha Puri, Project Manager, Scientist
Bristol-Myers Squibb, Co.
Introduction High concentration biologic formulations for parenteral administration are increasingly being sought to address the challenge of high dose and low dosing volume. This is especially true for the sub-cutaneous route of administration, for which the upper limit of the volume of injection t...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
Aastha Puri, Ajit S. Narang, Bristol-Myers Squibb, Genentech, High concentration biologics, Mary E. Krause, parenteral administration, Physical Stability, sub-cutaneous route
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
